Journal ArticleUnknown
A novel single‐chain‐Fv antibody against connective tissue growth factor attenuates bleomycin‐induced pulmonary fibrosis in mice
Authors
Author Affiliations
China Pharmaceutical University, Respiratory Clinical Trials, Pharmaceutical Biotechnology (Czechia), Czech Academy of Sciences, Institute of Biotechnology, ...
Published InRespirology
Year2011
Citations44
Abstract
BACKGROUND AND OBJECTIVE: Connective tissue growth factor (CTGF) has been identified as playing critical roles in fibrosis and is a promising therapeutic target. In a previous study, we used a phage display library to develop a humanized single-chain variable fragment antibody (scFv) against CTGF. In the present study, the protective effect of anti-CTGF scFv against bleomycin (BL)-induced pulmonary fibrosis was investigated in mice. METHODS: The expression of α-smooth muscle actin in human embryonic lung fibroblast (HELF) cells was analysed by western blotting. A mouse model of pulmonary fibrosis was established by tracheal injection of BL (5 mg/kg). Mice received anti-CTGF scFv (4 mg/kg, three times a week) by i.v. injection. The effects of anti-CTGF scFv were evaluated by leukocyte counts…
View at Publisher
BORR does not host full-text PDFs. The button above takes you to the original publisher.